comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 05:40:12 - browse：436

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Morphosys mixed study results for blood cancer drug

WSS

After Sarepta trial failure, Duchenne families brace for more debate

Hospitals look to new technology to keep health care workers safe

Poor hospice wound care hurts patients and families

Anthos stroke drug appears safer than common blood thinner

Infant mortality in U.S. rose last year for first time in decades: CDC

Key Senate panel to consider PBM, drug pricing reform package

explore

comprehensive

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Medical records are filled with copy

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

23andMe had bad news about my health. I wish a person had delivered it

Gene therapy’s promise and the high cost of hope

Psychedelics group wrestles with new pharma identity

Anthos stroke drug appears safer than common blood thinner

Virginia high school admissions case could be legal follow

Does good food count as health care? Study aims to find out

leisure time

Humans aren't the only ones with an imagination. Rats have it too

U.K. considers world's first use of meningitis vaccine to address gonorrhea

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout LOUD podcast: A CRISPR milestone, biotech mixology

NYU radiologists take on the challenge of expensive MRI machines

Astellas still sees hope in its gene therapy after four deaths

hotspot

focus

hotspot

leisure time